/
SYRE
$90.16+$2.27 (+2.58%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.6B
87M shares
52-week range
$14.00 – $102.06
86% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$75.66
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9M | $0 | $0 | $18.7M | $2.3M | $886.0K | $0 | $0 |
| Cost of revenue | $0 | $901.0K | $1.6M | $0 | $0 | $0 | $0 | $171.7M |
| Gross profit | $0 | −$901.0K | −$1.6M | $18.7M | $2.3M | $886.0K | $0 | −$171.7M |
| Gross margin | 0.0% | — | — | 100.0% | 100.0% | 100.0% | — | — |
| R&D | $36.7M | $64.6M | $59.6M | $57.1M | $58.6M | $89.5M | $162.8M | $171.7M |
| Operating income | −$45.5M | −$80.3M | −$81.5M | −$65.6M | −$84.8M | −$242.3M | −$208.6M | −$209.6M |
| EBITDA | −$45.2M | −$77.4M | −$79.3M | −$64.1M | −$82.0M | −$127.6M | −$208.0M | −$209.6M |
| Net income | −$44.3M | −$78.3M | −$80.9M | −$65.8M | −$83.8M | −$338.8M | −$208.0M | −$155.2M |
| Net margin | -1140.6% | — | — | -351.1% | -3598.8% | -38238.1% | — | — |
| EPS (diluted) | -53.25 | -61.23 | -37.89 | -25.02 | -24.86 | -46.15 | -3.18 | -1.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $88600 | $-3.01 | $-3.47–$-2.55 | 10 |
| 2027 | $166667 | $-3.21 | $-4.10–$-2.30 | 10 |
| 2028 | $200000 | $-3.74 | $-5.54–$-2.48 | 9 |
| 2029 | $50M | $-4.16 | $-4.16–$-4.16 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.23
Price
$90.16
Implied downside
-100%
Peer comparison
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
www.spyre.com- Employees
- 112
- IPO / List date
- Apr 7, 2016
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds SYRE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 30,936 | $463.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-08 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded SYRE yet.
